GlassScriptPhysician profile
Alyssa Finck
NPI 1073994273
$2,739.57
in general payments reported to CMS, 2019-2025
25 companies · $656 in 2025
The $656 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $240 · 2021: $180 · 2022: $494 · 2023: $505 · 2024: $530 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $977.68 | 2021-2025 | |
| Amgen INC. | $427.32 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $308.11 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $141.54 | 2019-2025 | |
| Lilly USA, LLC | $104.94 | 2021-2024 | Jardiance, Zepbound, Mounjaro |
| Neurocrine Biosciences, INC. | $98.42 | 2024-2025 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $89.66 | 2020-2024 | |
| Vanda Pharmaceuticals INC. | $77.17 | 2024-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $73.69 | 2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.63 | 2022-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $63.51 | 2022 | |
| Allergan, INC. | $48.98 | 2019-2020 | |
| Sanofi Pasteur INC. | $35.21 | 2021-2023 | |
| Mylan Specialty L.P. | $30.21 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $27.87 | 2025 | Uzedy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.22 | 2019-2024 | Jardiance |
| Organogenesis INC. | $23.67 | 2022 | |
| Nevro Corp. | $17.08 | 2022 | |
| Axsome Therapeutics, INC. | $16.92 | 2025 | Auvelity |
| Medtronic, INC. | $16.76 | 2025 | Intellis Adaptivestim |
| Acadia Pharmaceuticals INC | $16.02 | 2025 | Daybue |
| Genzyme Corporation | $15.15 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.98 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.64 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $10.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Finck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.